226 related articles for article (PubMed ID: 15969878)
1. Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections.
Edwards SJ; Emmas CE; Campbell HE
Curr Med Res Opin; 2005 May; 21(5):785-94. PubMed ID: 15969878
[TBL] [Abstract][Full Text] [Related]
2. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit.
Verwaest C;
Clin Microbiol Infect; 2000 Jun; 6(6):294-302. PubMed ID: 11168137
[TBL] [Abstract][Full Text] [Related]
3. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial.
Basoli A; Meli EZ; Mazzocchi P; Speranza V
Scand J Infect Dis; 1997; 29(5):503-8. PubMed ID: 9435041
[TBL] [Abstract][Full Text] [Related]
4. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients.
Cox CE; Holloway WJ; Geckler RW
Clin Infect Dis; 1995 Jul; 21(1):86-92. PubMed ID: 7578765
[TBL] [Abstract][Full Text] [Related]
5. [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study].
Tonelli F
Minerva Chir; 1997 Mar; 52(3):317-26. PubMed ID: 9148225
[TBL] [Abstract][Full Text] [Related]
6. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
Colardyn F; Faulkner KL
J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
[TBL] [Abstract][Full Text] [Related]
7. Treatment of obstetric and gynecologic infections with meropenem: comparison with imipenem/cilastatin.
Maggioni P; Di Stefano F; Facchini V; Irato S; Mancuso S; Colombo M; Massobrio M; Melis GB; Crosignani P
J Chemother; 1998 Apr; 10(2):114-21. PubMed ID: 9603636
[TBL] [Abstract][Full Text] [Related]
8. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections.
Nichols RL; Smith JW; Geckler RW; Wilson SE
South Med J; 1995 Apr; 88(4):397-404. PubMed ID: 7716590
[TBL] [Abstract][Full Text] [Related]
9. [A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections].
Hou F; Wu G; Zheng B
Zhonghua Nei Ke Za Zhi; 2001 Sep; 40(9):589-93. PubMed ID: 11758237
[TBL] [Abstract][Full Text] [Related]
10. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.
Geroulanos SJ
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():191-205. PubMed ID: 8543495
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care.
Edwards SJ; Campbell HE; Plumb JM
Eur J Health Econ; 2006 Mar; 7(1):72-8. PubMed ID: 16429296
[TBL] [Abstract][Full Text] [Related]
12. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group.
Hamacher J; Vogel F; Lichey J; Kohl FV; Diwok K; Wendel H; Lode H
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():121-33. PubMed ID: 8543488
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections.
Walters DJ; Solomkin JS; Paladino JA
Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):551-61. PubMed ID: 10662480
[TBL] [Abstract][Full Text] [Related]
14. Carbapenems versus other beta-lactams in the treatment of hospitalised patients with infection: a mixed treatment comparison.
Edwards SJ; Clarke MJ; Wordsworth S; Welton NJ
Curr Med Res Opin; 2009 Jan; 25(1):251-61. PubMed ID: 19210156
[TBL] [Abstract][Full Text] [Related]
15. A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus.
Embil JM; Soto NE; Melnick DA
Clin Ther; 2006 Aug; 28(8):1164-1174. PubMed ID: 16982293
[TBL] [Abstract][Full Text] [Related]
16. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
Brismar B; Malmborg AS; Tunevall G; Lindgren V; Bergman L; Mentzing LO; Nyström PO; Anséhn S; Bäckstrand B; Skau T
J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
[TBL] [Abstract][Full Text] [Related]
17. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia.
Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F
Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862
[TBL] [Abstract][Full Text] [Related]
18. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study.
Fabian TC; File TM; Embil JM; Krige JE; Klein S; Rose A; Melnick D; Soto NE
Surg Infect (Larchmt); 2005; 6(3):269-82. PubMed ID: 16201937
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients.
McKinnon PS; Paladino JA; Grayson ML; Gibbons GW; Karchmer AW
Clin Infect Dis; 1997 Jan; 24(1):57-63. PubMed ID: 8994756
[TBL] [Abstract][Full Text] [Related]
20. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
Kuo BI; Fung CP; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
